News Releases

-- Conference Call Scheduled for 4:30 p.m. ET --

Marketing campaign includes the brand's first-ever commercial spot introducing women to a birth control that puts them in control of their body, their sex life, and their pregnancy prevention.

Collaboration will provide resources about Phexxi® contraceptive vaginal gel to oncologists, pharmacists and associated healthcare providers

Evofem honored amongst best companies globally for outstanding innovation with first-in-class non-hormonal prescription contraceptive vaginal gel, Phexxi®

Approximately 25 Million Adult Women Covered by Medicaid

High Level of Interest from Clinical Sites Seeking to Participate in EVOGUARD Trial

Launched Phexxi™ (lactic acid, citric acid, potassium bitartrate) in U.S. for Hormone-free Contraception

-- Conference Call Scheduled for 5:00 p.m. ET --

- Live moderated video webcast discussion with members of Evofem management and Key Opinion Leader Patty Cason, RN, MS, FNP-BC, on Thursday, October 29th at 2:00 p.m. ET -

- Company plans to initiate Phase 3 STI trial by the end of 2020 -

- A First-in-Class Vaginal pH Modulator Designed for Use "In-the-Moment" -

- Advancing Precommercial Activities in Preparation for Phexxi™ Commercial Launch in September 2020 -

-- Conference Call Scheduled for 11:00 a.m. EDT --

- On-Track for September Launch of Phexxi™, the First FDA-Approved, Non-Hormonal, On-Demand Prescription Contraceptive Gel -

- A New Class of Female-Controlled Birth Control for Use In-The-Moment -

- On-Track for Phexxi™ PDUFA Date: May 25, 2020 -

-- Conference Call Scheduled for 11:00 a.m. ET --

- Funding to Support the Company's Launch and Commercialization Plans for Phexxi™ -

- Perfect Use Efficacy Up to 93.3%; Exploratory Findings Demonstrate Increased Sexual Satisfaction and Vaginal Lubrication; Company Provides Updated Safety Outcomes -

-- U.S. Food and Drug Administration (FDA) Grants Conditional Approval for New Brand Name - Phexxi™ --

-- Conference Call Scheduled for 11:00 a.m. EDT --

- Distinguished Career at the U.S. Food and Drug Administration in CDER and the Office of Women's Health; Significant Industry and Regulatory Expertise -

- Assigns PDUFA Goal Date of May 25, 2020 -

- AMPREVENCE Study Met Primary and Secondary Endpoints - a 50% Relative Risk Reduction in Chlamydia Infection and a 78% Relative Risk Reduction in Gonorrhea Infection Compared to Placebo -

- Submission Supported by Phase 3 AMPOWER Data -

- San Diego Business Journal Recognizes the City's Top 15 Female Business Leaders -

Company on Track for Amphora NDA Resubmission to the U.S. FDA

-- Conference Call Scheduled for 11:00 a.m. EST --